Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

which will help streamline access to FDA-approved Zepbound® (tirzepatide) single-dose vials for Noom’s members with an on-label prescription from their physician. This integration evolves Noom’s ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

which will help streamline access to FDA-approved Zepbound® (tirzepatide) single-dose vials for Noom’s members with an on-label prescription from their physician. This integration evolves Noom ...